AstraZeneca PLC
AstraZeneca's GHG Emissions Data Preview
In 2024, AstraZeneca completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy), and Scope 3 (indirect emissions across the value chain).
AstraZeneca has also provided a category-level breakdown for 12 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 2 | ||||
Market-Based | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Location-Based | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into AstraZeneca's Operational Emissions
In 2024, the total operational greenhouse gas (GHG) emissions of AstraZeneca amounted to 342,412 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2023, the total operational greenhouse gas (GHG) emissions of AstraZeneca decreased by 5.99%, showing that the company has made progress in taking action to reduce the climate impact of its operations.
AstraZeneca's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are AstraZeneca's Scope 1 emissions?
In 2024, the total Scope 1 emissions of AstraZeneca were 125,386 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Compared to the previous year (2023), AstraZeneca's Scope 1 emissions decreased by 30.69%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.
What are AstraZeneca's Scope 2 emissions?
In 2024, AstraZeneca reported Scope 2 greenhouse gas (GHG) emissions of 14,210 tCOâ‚‚e using the market-based method, and 217,026 tCOâ‚‚e using the location-based method.
Has AstraZeneca reduced its Scope 2 emissions over time?
Compared to the previous year (2023), AstraZeneca's Scope 2 emissions (Location-Based) rose by 18.38% in 2024, suggesting that the company faced challenges in reducing emissions from purchased electricity and energy
What methodology does AstraZeneca use for Scope 2 reporting?
In 2024, AstraZeneca reported its Scope 2 emissions using the market-based method and using the location-based method.
AstraZeneca's Scope 2 Emissions Over Time
- Total Scope 2 Location-Based
- Total Scope 2 Market-Based
Insights into AstraZeneca's Value Chain Emissions
In 2024, AstraZeneca reported 5,897,822 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.
The 2024 disclosure of AstraZeneca includes a breakdown across 12 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.
AstraZeneca's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are AstraZeneca's Scope 3 emissions?
In 2024, AstraZeneca reported total Scope 3 emissions of 5,897,822 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Approximately 76.34% of these emissions originated from upstream activities such as purchased goods and capital goods, while 23.66% came from downstream activities like product use, distribution, and end-of-life treatment.
Has AstraZeneca reduced its Scope 3 emissions over time?
Since 2019, AstraZeneca's Scope 3 emissions have remained relatively stable, indicating that AstraZeneca 's emissions have plateaued with no significant change in its value chain footprint.
Compared to the previous year (2023), AstraZeneca's Scope 3 emissions remained relatively stable, indicating that AstraZeneca 's emissions have plateaued with no significant change in its value chain footprint.
What categories of Scope 3 emissions does AstraZeneca disclose?
In 2024, AstraZeneca reported emissions for 12 out of the 15 Scope 3 categories defined by the GHG Protocol.
This reflects a high level of granularity and transparency in the company's emissions reporting.
What are the main sources of AstraZeneca's Scope 3 emissions?
In 2024, the largest contributors to AstraZeneca's Scope 3 emissions were:
- Purchased Goods and Services (Cat. 1): 3,751,482 tCOâ‚‚e (63.61%)
- Use of Sold Products (Cat. 11): 1,377,449 tCOâ‚‚e (23.36%)
- Upstream Transportation and Distribution (Cat. 4): 235,462 tCOâ‚‚e (3.99%)
AstraZeneca's Scope 3 Emissions by Categories
Insights into AstraZeneca's Total Carbon Footprint
In 2024, AstraZeneca reported a total carbon footprint of 6,240,234 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 0.66% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output.
The largest contributor to AstraZeneca's total carbon footprint was Scope 3 emissions, accounting for 94.51% of the company's total carbon footprint, followed by Scope 2 emissions at 3.48%.